FDA Approves Dostarlimab for Certain Rectal Cancer Patients

• On Oct. 19, the FDA approved dostarlimab (Jemperli) for treating a specific type of rectal cancer.
• The approval is for stage II/III patients with microsatellite instability-high (MSI-H) rectal cancer.
• Dostarlimab is an immune-based treatment that may allow some patients to avoid surgery, chemotherapy, and radiation.
• This approval is considered a significant advancement in cancer treatment.
• The treatment works by targeting specific genetic mutations in cancer cells.